Apogenix
Apogenix - protein therapeutics for the treatment of cancer.
Launch date
Employees
Market cap
-
Enterprise valuation
$91—137m (Dealroom.co estimates Dec 2021.)
Company register number HRB 723746 (Mannheim)
Heidelberg Baden-Württemberg (HQ)
Financials
Estimates*
| EUR | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
| Revenues | - | <1m | <1m | <1m | 1.0m | 1.0m | 1.0m |
| % growth | - | - | 14 % | (32 %) | 88 % | - | - |
| EBITDA | - | - | (10.0m) | (8.0m) | (8.6m) | - | - |
| % EBITDA margin | - | - | (1240 %) | (1459 %) | (826 %) | - | - |
| Profit | (11.8m) | (19.4m) | (11.9m) | (10.4m) | (11.6m) | - | - |
| % profit margin | - | (2729 %) | (1464 %) | (1882 %) | (1115 %) | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
€27.5m | Series B | ||
$10.0m | Series C | ||
| N/A | €3.0m | Grant | |
* | €20.7m | Late VC | |
| Total Funding | $66.3m | ||
Related Content
Recent News about Apogenix
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.